Shenzhen Chipscreen Biosciences Co Ltd
SSE:688321

Watchlist Manager
Shenzhen Chipscreen Biosciences Co Ltd Logo
Shenzhen Chipscreen Biosciences Co Ltd
SSE:688321
Watchlist
Price: 21.02 CNY -8.49% Market Closed
Market Cap: 8.6B CNY
Have any thoughts about
Shenzhen Chipscreen Biosciences Co Ltd?
Write Note

Shenzhen Chipscreen Biosciences Co Ltd
Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shenzhen Chipscreen Biosciences Co Ltd
Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Shenzhen Chipscreen Biosciences Co Ltd
SSE:688321
Common Stock
ÂĄ407.8m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Common Stock
ÂĄ52k
CAGR 3-Years
0%
CAGR 5-Years
120%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Common Stock
ÂĄ603.3m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
14%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Common Stock
ÂĄ6.4B
CAGR 3-Years
0%
CAGR 5-Years
8%
CAGR 10-Years
16%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Common Stock
ÂĄ1.8B
CAGR 3-Years
12%
CAGR 5-Years
11%
CAGR 10-Years
6%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Common Stock
ÂĄ401m
CAGR 3-Years
4%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shenzhen Chipscreen Biosciences Co Ltd
Glance View

Market Cap
8.6B CNY
Industry
Pharmaceuticals

Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research, development, and sale of small molecule drugs. The company is headquartered in Shenzhen, Guangdong and currently employs 909 full-time employees. The company went IPO on 2019-08-12. The firm focuses on the research and development of original innovative drugs in five therapeutic areas, including malignant tumors, metabolic diseases, autoimmune diseases, central nervous system diseases and anti-virus. The firm's main products include Chidamide, Siglitazone, Cioroni and CS12192. The firm mainly conducts its businesses in the domestic market.

Intrinsic Value
12.22 CNY
Overvaluation 42%
Intrinsic Value
Price

See Also

What is Shenzhen Chipscreen Biosciences Co Ltd's Common Stock?
Common Stock
407.8m CNY

Based on the financial report for Sep 30, 2024, Shenzhen Chipscreen Biosciences Co Ltd's Common Stock amounts to 407.8m CNY.

What is Shenzhen Chipscreen Biosciences Co Ltd's Common Stock growth rate?
Common Stock CAGR 5Y
0%

Over the last year, the Common Stock growth was -1%.

Back to Top